Sylvie Détry

Apave SA specializes in tests for quality control. The company was founded in 1867 and is headquartered in Paris, France.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

Deloitte SAS provides legal, accounting, auditing, and consulting services. It offers solutions in risk management, mergers and acquisitions, tax systems, audit and assurance, and human capital. The company was founded on January 16, 2001 and is headquartered in Paris, France.

Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France.

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.

Framatome SAS engages in the construction, operations, and maintenance of nuclear reactors. It offers heavy primary loop components, mobile component for nuclear facilities, nuclear engineering, nuclear maintenance, fabrication of fuel assemblies for reactors, and instrumentation and control services. The company was founded in 1958 and is headquartered in Courbevoie, France.

Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Atlanpole Biotherapies provides immunotherapy, regenerative medicine, and radio pharmacy bio cluster services. The company is based in Nantes, France.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Wolf-Medizintechnik GmbH provides services in the fields of x-ray technology and electro medicine. It develops and manufactures systems for superficial and orthovoltage x-ray therapy and special systems used in medicine and non-destructive testing. It also distributes diagnostic x-ray equipment and provides technical and maintenance services. The company was founded in 1990 and is headquartered in St. Gangloff, Germany.

Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.

Big Booster's is an international accelerator that focuses on positive impact. The French company has accelerated 278 startups to date. The private company was founded by Didier Hoch and has four years of experience in accelerating startups.

Olgram SAS provides scientific research and development services. The company is based in Brehan, France. The French company was founded by Hervé Balusson, Maryvonne Hiance, Karim Asehnoune, Pi Nyvall Collén, Pierre Rocheteau. Pierre Rocheteau has been the CEO since incorporation.

Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018.

Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables.